Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice

FASEB Journal

Volumn 28, Issue 6, 2014, Pages 2655-2666

  Benesch, Matthew G K ^a   Tang, Xiaoyun ^a   Maeda, Tatsuo ^c   Ohhata, Akira ^c   Zhao, Yuan Y ^a   Kok, Bernard P C ^a   Dewald, Jay ^a   Hitt, Mary ^a   Curtis, Jonathan M ^a   McMullen, Todd P W ^b   Brindley, David N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ONO PHARMACEUTICAL CO   (Japan)

Author keywords

Adipose tissue lysophosphatidate sphingosine 1 phosphate syngeneic mouse model

Indexed keywords

AUTOTAXIN; AUTOTAXIN INHIBITOR; LYSOPHOSPHATIDIC ACID; MESSENGER RNA; ONO 8430506; PROTEIN INHIBITOR; SPHINGOSINE 1 PHOSPHATE; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; LUNG METASTASIS; MASS SPECTROMETRY; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; WESTERN BLOTTING;

ADIPOSE TISSUE; LYSOPHOSPHATIDATE; SPHINGOSINE 1-PHOSPHATE; SYNGENEIC MOUSE MODEL;

ANIMALS; CARBOLINES; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; LUNG NEOPLASMS; LYSOPHOSPHOLIPIDS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES;

EID: 84901854094     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.13-248641     Document Type: Article

References (63)

1. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., and Thun, M. J. (2006) Cancer statistics, 2006. Cancer J. Clin. 56, 106-130
2. Paridaens, R., Biganzoli, L., Bruning, P., Klijn, J. G., Gamucci, T., Houston, S., Coleman, R., Schachter, J., Van Vreckem, A., Sylvester, R., Awada, A., Wildiers, J., and Piccart, M. (2000) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over. J. Clin. Oncol. 18, 724-733 (Pubitemid 30106602)
3. Bekele, R., and Brindley, D. N. (2012) Role of autotaxin and lysophosphatidate in cancer progression and resistance to chemotherapy and radiotherapy. Clin. Lipidol. 7, 313-328
4. Brindley, D. N., Lin, F. T., and Tigyi, G. J. (2013) Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy. Biochim. Biophys. Acta 1831, 74-85
5. Van Meeteren, L. A., Ruurs, P., Stortelers, C., Bouwman, P., van Rooijen, M. A., Pradere, J. P., Pettit, T. R., Wakelam, M. J., Saulnier-Blache, J. S., Mummery, C. L., Moolenaar, W. H., and Jonkers, J. (2006) Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell. Biol. 26, 5015-5022 (Pubitemid 43955815)
6. Koike, S., Keino-Masu, K., Ohto, T., Sugiyama, F., Takahashi, S., and Masu, M. (2009) Autotaxin/lysophospholipase D-mediated lysophosphatidic acid signaling is required to form distinctive large lysosomes in the visceral endoderm cells of the mouse yolk sac. J. Biol. Chem. 284, 33561-33570
7. Nakanaga, K., Hama, K., and Aoki, J. (2010) Autotaxin - an LPA producing enzyme with diverse functions. J. Biochem. 148, 13-24
8. van Meeteren, L. A., and Moolenaar, W. H. (2007) Regulation and biological activities of the autotaxin-LPA axis. Prog. Lipid Res. 46, 145-160 (Pubitemid 46654231)
9. Samadi, N., Bekele, R., Capatos, D., Venkatraman, G., Sariahmetoglu, M., and Brindley, D. N. (2011) Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance. Biochimie (Paris) 93, 61-70
10. Nam, S. W., Clair, T., Kim, Y. S., McMarlin, A., Schiffmann, E., Liotta, L. A., and Stracke, M. L. (2001) Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res. 61, 6938-6944 (Pubitemid 32896522)
11. Umezu-Goto, M., Kishi, Y., Taira, A., Hama, K., Dohmae, N., Takio, K., Yamori, T., Mills, G. B., Inoue, K., Aoki, J., and Arai, H. (2002) Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol. 158, 227-233
12. Yang, S. Y., Lee, J., Park, C. G., Kim, S., Hong, S., Chung, H. C., Min, S. K., Han, J. W., Lee, H. W., and Lee, H. Y. (2002) Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin. Exp. Metastasis 19, 603-608 (Pubitemid 35454570)
13. Kehlen, A., Englert, N., Seifert, A., Klonisch, T., Dralle, H., Langner, J., and Hoang-Vu, C. (2004) Expression, regulation and function of autotaxin in thyroid carcinomas. Int. J. Cancer J. 109, 833-838 (Pubitemid 38500739)
14. Liu, S., Umezu-Goto, M., Murph, M., Lu, Y., Liu, W., Zhang, F., Yu, S., Stephens, L. C., Cui, X., Murrow, G., Coombes, K., Muller, W., Hung, M. C., Perou, C. M., Lee, A. V., Fang, X., and Mills, G. B. (2009) Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 15, 539-550
15. Sukocheva, O. A., Wang, L., Albanese, N., Pitson, S. M., Vadas, M. A., and Xia, P. (2003) Sphingosine kinase transmits estrogen signaling in human breast cancer cells. Mol. Endocrinol. 17, 2002-2012 (Pubitemid 37281793)
16. Choi, J. W., and Chun, J. (2013) Lysophospholipids and their receptors in the central nervous system. Biochim. Biophys. Acta 1831, 20-32
17. Brindley, D. N., and Pilquil, C. (2009) Lipid phosphate phosphatases and signaling. J. Lipid Res. 50(Suppl.), S225-S230
18. Brindley, D. N., Pilquil, C., Sariahmetoglu, M., and Reue, K. (2009) Phosphatidate degradation: phosphatidate phosphatases (lipins) and lipid phosphate phosphatases. Biochim. Biophys. Acta 1791, 956-961
19. So, J., Wang, F. Q., Navari, J., Schreher, J., and Fishman, D. A. (2005) LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). Gynecologic Oncol. 97, 870-878 (Pubitemid 40824659)
20. Murph, M. M., Hurst-Kennedy, J., Newton, V., Brindley, D. N., and Radhakrishna, H. (2007) Lysophosphatidic acid decreases the nuclear localization and cellular abundance of the p53 tumor suppressor in A549 lung carcinoma cells. Mol. Cancer Res. 5, 1201-1211 (Pubitemid 350137115)
21. Popnikolov, N. K., Dalwadi, B. H., Thomas, J. D., Johannes, G. J., and Imagawa, W. T. (2012) Association of autotaxin and lysophosphatidic acid receptor 3 with aggressiveness of human breast carcinoma. Tumour Biol. 33, 2237-2243
22. Gaetano, C. G., Samadi, N., Tomsig, J. L., Macdonald, T. L., Lynch, K. R., and Brindley, D. N. (2009) Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells. Mol. Carcinog. 48, 801-809
23. Euer, N., Schwirzke, M., Evtimova, V., Burtscher, H., Jarsch, M., Tarin, D., and Weidle, U. H. (2002) Identification of genes associated with metastasis of mammary carcinoma in metastatic versus non-metastatic cell lines. Anticancer Res. 22, 733-740 (Pubitemid 34475222)
24. Samadi, N., Gaetano, C., Goping, I. S., and Brindley, D. N. (2009) Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. Oncogene 28, 1028-1039
25. Samadi, N., Bekele, R. T., Goping, I. S., Schang, L. M., and Brindley, D. N. (2011) Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest. PLoS One 6, e20608
26. Zhang, R., Wang, J., Ma, S., Huang, Z., and Zhang, G. (2011) Requirement of Osteopontin in migration and the protection against Taxol-induced apoptosis via ATX-LPA axis in SGC7901 cells. BMC Cell Biol. 12, 11
27. Vidot, S., Witham, J., Agarwal, R., Greenhough, S., Bamrah, H. S., Tigyi, G. J., Kaye, S. B., and Richardson, A. (2010) Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. Cell. Signal. 22, 926-935
28. Deng, W., Shuyu, E., Tsukahara, R., Valentine, W. J., Durgam, G., Gududuru, V., Balazs, L., Manickam, V., Arsura, M., Van-Middlesworth, L., Johnson, L. R., Parrill, A. L., Miller, D. D., and Tigyi, G. (2007) The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury. Gastroenterology 132, 1834-1851 (Pubitemid 46691269)
29. Shida, D., Takabe, K., Kapitonov, D., Milstien, S., and Spiegel, S. (2008) Targeting SphK1 as a new strategy against cancer. Curr. Drug Targets 9, 662-673
30. Sukocheva, O., Wang, L., Verrier, E., Vadas, M. A., and Xia, P. (2009) Restoring endocrine response in breast cancer cells by inhibition of the sphingosine kinase-1 signaling pathway. Endocrinology 150, 4484-4492
31. English, D., Garcia, J. G., and Brindley, D. N. (2001) Plateletreleased phospholipids link haemostasis and angiogenesis. Cardiovasc. Res. 49, 588-599 (Pubitemid 32146422)
32. Pyne, N. J., and Pyne, S. (2010) Sphingosine 1-phosphate and cancer. Nat. Rev. Cancer 10, 489-503
33. Murata, J., Lee, H. Y., Clair, T., Krutzsch, H. C., Arestad, A. A., Sobel, M. E., Liotta, L. A., and Stracke, M. L. (1994) cDNA cloning of the human tumor motility-stimulating protein, autotaxin, reveals a homology with phosphodiesterases. J. Biol. Chem. 269, 30479-30484 (Pubitemid 24376528)
34. Morimoto, T., Nakatani, S., Ohhata, A., and Sugiyama, T., inventors; Ono Pharmaceutical Co. Ltd., assignee (2012, December 1) Tetrahydrocarboline derivative. World patent WO2012005227. Japanese.
35. Imamura, S., and Horiuti, Y. (1978) Enzymatic determination of phospholipase D activity with choline oxidase. J. Biochem. (Tokyo) 83, 677-680 (Pubitemid 8307759)
36. Nakamura, K., Ohkawa, R., Okubo, S., Tozuka, M., Okada, M., Aoki, S., Aoki, J., Arai, H., Ikeda, H., and Yatomi, Y. (2007) Measurement of lysophospholipase D/autotaxin activity in human serum samples. Clin. Biochem. 40, 274-277 (Pubitemid 46108705)
37. Scherer, M., Leuthauser-Jaschinski, K., Ecker, J., Schmitz, G., and Liebisch, G. (2010) A rapid and quantitative LC-MS/MS method to profile sphingolipids. J. Lipid Res. 51, 2001-2011
38. Scherer, M., Schmitz, G., and Liebisch, G. (2009) High-throughput analysis of sphingosine 1-phosphate, sphinganine 1-phosphate, and lysophosphatidic acid in plasma samples by liquid chromatographytandem mass spectrometry. Clin. Chem. 55, 1218-1222
39. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685
40. Albers, H. M., and Ovaa, H. (2012) Chemical evolution of autotaxin inhibitors. Chem. Rev. 112, 2593-2603
41. Barbayianni, E., Magrioti, V., Moutevelis-Minakakis, P., and Kokotos, G. (2013) Autotaxin inhibitors: a patent review. Exp. Opin. Therap. Patents 23, 1123-1132
42. Fourcade, O., Simon, M. F., Viode, C., Rugani, N., Leballe, F., Ragab, A., Fournie, B., Sarda, L., and Chap, H. (1995) Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell 80, 919-927
43. Li, H., Zhao, Z., Wei, G., Yan, L., Wang, D., Zhang, H., Sandusky, G. E., Turk, J., and Xu, Y. (2010) Group VIA phospholipase A2 in both host and tumor cells is involved in ovarian cancer development. FASEB J. 24, 4103-4116
44. Clair, T., Aoki, J., Koh, E., Bandle, R. W., Nam, S. W., Ptaszynska, M. M., Mills, G. B., Schiffmann, E., Liotta, L. A., and Stracke, M. L. (2003) Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res. 63, 5446-5453 (Pubitemid 37139863)
45. Camerer, E., Regard, J. B., Cornelissen, I., Srinivasan, Y., Duong, D. N., Palmer, D., Pham, T. H., Wong, J. S., Pappu, R., and Coughlin, S. R. (2009) Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. J. Clin. Invest. 119, 1871-1879
46. Tao, K., Fang, M., Alroy, J., and Sahagian, G. G. (2008) Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer 8, 228
47. Jeon, Y. H., Choi, Y., Kang, J. H., Kim, C. W., Jeong, J. M., Lee, D. S., and Chung, J.-K. (2007) Immune response to firefly luciferase as a naked DNA. Cancer Biol. Ther. 6, 781-786 (Pubitemid 47328362)
48. David, M., Wannecq, E., Descotes, F., Jansen, S., Deux, B., Ribeiro, J., Serre, C. M., Gres, S., Bendriss-Vermare, N., Bollen, M., Saez, S., Aoki, J., Saulnier-Blache, J. S., Clezardin, P., and Peyruchaud, O. (2010) Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS One 5, e9741
49. Houben, A. J., van Wijk, X. M., van Meeteren, L. A., van Zeijl, L., van de Westerlo, E. M., Hausmann, J., Fish, A., Perrakis, A., van Kuppevelt, T. H., and Moolenaar, W. H. (2013) The polybasic insertion in autotaxin alpha confers specific binding to heparin and cell surface heparan sulfate proteoglycans. J. Biol. Chem. 288, 510-519
50. Fulkerson, Z., Wu, T., Sunkara, M., Kooi, C. V., Morris, A. J., and Smyth, S. S. (2011) Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells. J. Biol. Chem. 286, 34654-34663
51. Hausmann, J., Kamtekar, S., Christodoulou, E., Day, J. E., Wu, T., Fulkerson, Z., Albers, H. M., van Meeteren, L. A., Houben, A. J., van Zeijl, L., Jansen, S., Andries, M., Hall, T., Pegg, L. E., Benson, T. E., Kasiem, M., Harlos, K., Kooi, C. W., Smyth, S. S., Ovaa, H., Bollen, M., Morris, A. J., Moolenaar, W. H., and Perrakis, A. (2011) Structural basis of substrate discrimination and integrin binding by autotaxin. Nat. Struct. Mol. Biol. 18, 198-204
52. Boucher, J., Quilliot, D., Praderes, J. P., Simon, M. F., Gres, S., Guigne, C., Prevot, D., Ferry, G., Boutin, J. A., Carpene, C., Valet, P., and Saulnier-Blache, J. S. (2005) Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression. Diabetologia 48, 569-577 (Pubitemid 40487305)
53. Dusaulcy, R., Rancoule, C., Gres, S., Wanecq, E., Colom, A., Guigne, C., van Meeteren, L. A., Moolenaar, W. H., Valet, P., and Saulnier-Blache, J. S. (2011) Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid. J. Lipid Res. 52, 1247-1255
54. Ferry, G., Tellier, E., Try, A., Gres, S., Naime, I., Simon, M. F., Rodriguez, M., Boucher, J., Tack, I., Gesta, S., Chomarat, P., Dieu, M., Raes, M., Galizzi, J. P., Valet, P., Boutin, J. A., and Saulnier-Blache, J. S. (2003) Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Upregulated expression with adipocyte differentiation and obesity. J. Biol. Chem. 278, 18162-18169 (Pubitemid 36799431)
55. Federico, L., Ren, H., Mueller, P. A., Wu, T., Liu, S., Popovic, J., Blalock, E. M., Sunkara, M., Ovaa, H., Albers, H. M., Mills, G. B., Morris, A. J., and Smyth, S. S. (2012) Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice. Mol. Endocrinol. 26, 786-797
56. Sundaram, S., Johnson, A. R., and Makowski, L. (2013) Obesity, metabolism and the microenvironment: links to cancer. J. Carcinog. 12, 19
57. De Pergola, G., and Silvestris, F. Obesity as a major risk factor for cancer. J. Obes. 2013:291546, 2013
58. Benesch, M. G. K., Ko, Y., McMullen, T. P. W., and Brindley, D. N. (2014) Autotaxin in the crosshairs: Taking aim at cancer and other inflammatory conditions. [E-pub ahead of print] FEBS Lett. 10.1016/j.febslet.2014.02.009
59. Nikitopoulou, I., Oikonomou, N., Karouzakis, E., Sevastou, I., Nikolaidou-Katsaridou, N., Zhao, Z., Mersinias, V., Armaka, M., Xu, Y., Masu, M., Mills, G. B., Gay, S., Kollias, G., and Aidinis, V. (2012) Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. J. Exp. Med. 209, 925-933
60. Hozumi, H., Hokari, R., Kurihara, C., Narimatsu, K., Sato, H., Sato, S., Ueda, T., Higashiyama, M., Okada, Y., Watanabe, C., Komoto, S., Tomita, K., Kawaguchi, A., Nagao, S., and Miura, S. (2013) Involvement of autotaxin/lysophospholipase D expression in intestinal vessels in aggravation of intestinal damage through lymphocyte migration. Lab. Invest. 93, 508-519
61. Nakamura, K., Igarashi, K., Ohkawa, R., Yokota, H., Masuda, A., Nakagawa, S., Yano, T., Ikeda, H., Aoki, J., and Yatomi, Y. (2012) Serum autotaxin is not a useful biomarker for ovarian cancer. Lipids 47, 927-930
62. Masuda, A., Nakamura, K., Izutsu, K., Igarashi, K., Ohkawa, R., Jona, M., Higashi, K., Yokota, H., Okudaira, S., Kishimoto, T., Watanabe, T., Koike, Y., Ikeda, H., Kozai, Y., Kurokawa, M., Aoki, J., and Yatomi, Y. (2008) Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma. Br. J. Haematol. 143, 60-70
63. Nakai, Y., Ikeda, H., Nakamura, K., Kume, Y., Fujishiro, M., Sasahira, N., Hirano, K., Isayama, H., Tada, M., Kawabe, T., Komatsu, Y., Omata, M., Aoki, J., Koike, K., and Yatomi, Y. (2011) Specific increase in serum autotaxin activity in patients with pancreatic cancer. Clin. Biochem. 44, 576-581